Immunotherapy最新文献_第2页

Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors. 接受免疫检查点抑制剂治疗的肺癌患者发生免疫相关不良事件的真实世界数据。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-04-04 DOI: 10.1080/1750743X.2025.2488728

Xiao Hu, Angie Mae Rodday, Anastasia Gurinovich, Stacey Pan, Yana V Salei, Jeffrey H Lin, Margaret M Byrne, Yu Cao, Lori Pai, Susan K Parsons

{"title":"Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors.","authors":"Xiao Hu, Angie Mae Rodday, Anastasia Gurinovich, Stacey Pan, Yana V Salei, Jeffrey H Lin, Margaret M Byrne, Yu Cao, Lori Pai, Susan K Parsons","doi":"10.1080/1750743X.2025.2488728","DOIUrl":"10.1080/1750743X.2025.2488728","url":null,"abstract":"Background: Immune-checkpoint inhibitors (ICIs) have revolutionized lung cancer (LC) treatment; however, immune-related adverse effects (irAEs) may occur. The risk factors of irAEs and the impact of irAEs on patient outcomes in LC remain uncertain.Materials and methods: irAEs within 12 months of ICI initiation in LC patients who initiated ICIs 2018-2021 were identified. Cause-specific Cox regression was used to assess risk factors for irAEs with the competing risk of death; a subset analysis was done among non-small cell lung cancer (NSCLC) group. Multivariable Cox regressions were used to evaluate the impact of irAEs on progression-free survival (PFS) and overall survival (OS).Results: Of 125 patients, 50 irAEs occurred in 39 patients. Small cell lung cancer (SCLC) histology was associated with a higher risk of irAEs (Hazard ratio (HR) = 2.73, 95% CI [1.17, 6.35], p = 0.020) than NSCLC. In NSCLC subset, programmed death-ligand 1 (PDL1) positivity (HR = 2.68, 95% CI [1.10. 6.53], p = 0.030) was identified as a risk factor. irAEs were not significantly associated with PFS (HR = 0.69, p = 0.204) or OS (HR = 0.72, p = 0.353).Conclusion: SCLC histology and PDL1 positivity were associated with irAEs, and the occurrence of irAEs showed no impact on survival in LC patients. Future studies are required to validate the findings.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"321-329"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary. 评估COMPACT研究中风湿病患者使用SDZ ETN（一种依那西普生物类似药）的实际治疗效果：简单的语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-05-12 DOI: 10.1080/1750743X.2025.2493039

Marc Schmalzing, Herbert Kellner, Ayman Askari, Javier de Toro Santos, Julio Cesar Vazquez Perez-Coleman, Rosario Foti, Sławomir Jeka, Yannick Allanore, Peter Peichl, Martin Oehri, Neil Betteridge, Cristofer Salvati, Elisa Romero, Ines Brueckmann, Tom Sheeran

引用次数: 0

Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update. 肌肉浸润性膀胱癌的新辅助免疫治疗：2025年更新。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-05-06 DOI: 10.1080/1750743X.2025.2501929

Ilias Giannakodimos, Afroditi Ziogou, Alexios Giannakodimos, Konstantinos Tzelepis, Zisis Kratiras, Evangelos Fragkiadis, Ioannis Zachos, Vasileios Tzortzis, Michael Chrisofos, Nikolaos Charalampakis

{"title":"Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update.","authors":"Ilias Giannakodimos, Afroditi Ziogou, Alexios Giannakodimos, Konstantinos Tzelepis, Zisis Kratiras, Evangelos Fragkiadis, Ioannis Zachos, Vasileios Tzortzis, Michael Chrisofos, Nikolaos Charalampakis","doi":"10.1080/1750743X.2025.2501929","DOIUrl":"10.1080/1750743X.2025.2501929","url":null,"abstract":"Urothelial bladder cancer constitutes one of the most common malignancies of the urinary tract, comprising 90-95% of urothelial carcinomas. Only 25% of patients present with muscle-invasive bladder cancer (MIBC), a neoplasm associated with higher morbidity and mortality. Concerning localized MIBC, cisplatin-based chemotherapy remains the standard neoadjuvant treatment; however, its survival benefits are limited, and its use is restricted to patients with adequate performance status and renal function. Current clinical guidelines recommend neoadjuvant immunotherapy as a first- or second-line option, especially for cisplatin-ineligible patients. Neoadjuvant immunotherapy as monotherapy or in combination with chemotherapy or other immune checkpoint inhibitors is under active investigation. In the ABACUS trial, atezolizumab monotherapy achieved a 31% pathological complete response (pCR). The NCT03520491 trial showed a pCR rate of up to 46% with nivolumab and ipilimumab. The KCT0003804 trial, evaluating immunotherapy plus chemotherapy, reported a 59% pCR and 81.8% 1-year disease-free survival. This review provides an updated overview of clinical trials on neoadjuvant immunotherapy for MIBC, highlighting its therapeutic potential and safety.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"447-455"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects. rozanolizumab治疗重症肌无力：突破性治疗和未来展望

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-04-25 DOI: 10.1080/1750743X.2025.2491295

Alexandria Matic, Vera Bril

{"title":"Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects.","authors":"Alexandria Matic, Vera Bril","doi":"10.1080/1750743X.2025.2491295","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2491295","url":null,"abstract":"Myasthenia gravis is a rare chronic autoimmune disorder affecting the post-synaptic neuromuscular junction, primarily mediated by pathogenic immunoglobulin G (IgG) targeting specific proteins like acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), and low-density lipoprotein receptor-related protein 4 (LRP4). Modulating pathogenic IgG is a promising approach for disease management. Rozanolixizumab, a human IgG4 neonatal Fc receptor (FcRn) inhibitor, enhances the degradation of pathogenic IgG by 78%, marking a significant advancement in treating generalized myasthenia gravis. It offers effective management for patients with AChR or MuSK antibodies and is administered subcutaneously with mild to moderate adverse events. However, the safety and efficacy of rozanolixizumab require further validation through real-world post-marketing studies. If current trial results are confirmed, rozanolixizumab may become a preferred treatment option for myasthenia gravis in the near future. This review examines clinical trials evaluating the pharmacokinetics, efficacy, and safety of rozanolixizumab in patients with generalized myasthenia gravis and discusses ongoing trials and future research directions.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"17 5","pages":"309-316"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy. 免疫检查点抑制剂和化疗对胃癌患者Khorana风险评分的影响

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-05-07 DOI: 10.1080/1750743X.2025.2501922

Junmin Song, Ahmed Ashraf Morgan, Jaeun Ahn, Wing Fai Li, Yu Chang, Yu-Cheng Chang, Muhammad Fahimuddin, Kuan-Yu Chi, Lawrence W Wu, Cho-Han Chiang

{"title":"Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy.","authors":"Junmin Song, Ahmed Ashraf Morgan, Jaeun Ahn, Wing Fai Li, Yu Chang, Yu-Cheng Chang, Muhammad Fahimuddin, Kuan-Yu Chi, Lawrence W Wu, Cho-Han Chiang","doi":"10.1080/1750743X.2025.2501922","DOIUrl":"10.1080/1750743X.2025.2501922","url":null,"abstract":"Introduction: Patients with gastric cancer are at a high risk of venous thromboembolism (VTE), and immune checkpoint inhibitors (ICIs) may further increase this risk. While the Khorana Risk Score (KRS) has been validated primarily in chemotherapy-treated populations, its utility in ICI-treated patients remains unclear.Methods: Using the TriNetX Global Collaborative Network, we analyzed data from 2782 patients with gastric cancer treated with ICIs. Patients were stratified into high-risk (KRS ≥3) and intermediate-risk (KRS = 2) groups based on pre-treatment laboratory values and BMI. Cox proportional-hazards analyses were performed to evaluate the association between KRS and outcomes, including VTE, all-cause mortality, and arterial thrombosis, over a one-year follow-up period.Results: High-risk patients had a 26% higher risk of VTE (HR: 1.26, [95% CI: 1.06-1.50]) and a 43% higher risk of all-cause mortality (HR: 1.43, [95% CI: 1.27-1.62]) compared to intermediate-risk patients. The incidence of deep vein thrombosis (DVT) was also significantly higher in the high-risk group (HR: 1.27, [95% CI: 1.01-1.59]), but no significant differences were observed for pulmonary embolism (PE) or arterial thrombosis.Conclusion: These findings suggest the KRS may effectively stratify VTE risk and mortality in gastric cancer patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"419-424"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the role of immune checkpoint inhibitors in solitary fibrous tumors. 探讨免疫检查点抑制剂在孤立性纤维性肿瘤中的作用。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-03-31 DOI: 10.1080/1750743X.2025.2485670

Tarek Assi, Tania Moussa, Axel Le Cesne

引用次数: 0

CD33-D2 isoform characterization for advancement of its therapeutic potential. CD33-D2异构体的表征及其治疗潜力的进展。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-04-24 DOI: 10.1080/1750743X.2025.2493038

Vivek M Shastri, Srideshikan Sargur Madabushi, Susanta K Hui, Jatinder K Lamba

{"title":"CD33-D2 isoform characterization for advancement of its therapeutic potential.","authors":"Vivek M Shastri, Srideshikan Sargur Madabushi, Susanta K Hui, Jatinder K Lamba","doi":"10.1080/1750743X.2025.2493038","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2493038","url":null,"abstract":"Purpose: While CD33 directed immunotherapies have caught significant interest in recent years, the only approved antibody-drug conjugate targeting this antigen for AML is gemtuzumab ozogamicin, which targets the IgV-domain of CD33. Unfortunately, in its current form, these are not effective in a significant proportion of patients due to the presence of a splicing SNP resulting in the loss of IgV-domain. This, however, can be mitigated by targeting the IgC2-domain of CD33; thus, this study aimed to characterize CD33-D2 isoform using the recently developed CD33-D2-targeting antibody HL2541.Methods: Genetically engineered AML cell lines expressing CD33 isoforms were tested for antibody-bound internalization and response to GO in vitro. AML-bearing NSG-SGM3 mice were used to evaluate CD33-D2 localization and targeting by the HL2541 antibody in vivo.Results: HL2541-bound-CD33-D2 is internalized similar to CD33-FL upon binding the antibody component of GO. Co-existence of both isoforms compromises the internalization by >2.5-3-fold for each isoform in the AML cell lines, further resulting in 7-9.5-fold higher IC50 values compared to cells expressing only CD33-FL. Finally, we demonstrate that AML cells expressing CD33-D2 localize to bones in mice and are targeted by HL2541antibody in vivo.Conclusion: The results establish the relevance of targeting IgC domain as an alternative immunotarget to supplement AML chemotherapy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"17 5","pages":"347-354"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease. 评估阿替利单抗作为慢性移植物抗宿主病的治疗选择。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-05-08 DOI: 10.1080/1750743X.2025.2501928

Tania Dexter, Chloe Anthias, Emma Nicholson

{"title":"Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease.","authors":"Tania Dexter, Chloe Anthias, Emma Nicholson","doi":"10.1080/1750743X.2025.2501928","DOIUrl":"10.1080/1750743X.2025.2501928","url":null,"abstract":"Allogeneic stem cell transplantation represents the only curative option for many patients with high risk hematological malignancies but is associated with a number of severe complications. Of these, chronic graft versus host disease (cGVHD) is the leading cause of late non-relapse mortality and of much morbidity. For over 30 years, glucocorticoids have been the mainstay of first line therapy, yet approximately 50% patients are refractory or dependent and traditionally there have been few options for these patients. In recent years, newer treatments including ruxolitinib and belumosudil have shown success in the second and third line settings. However, further effective nontoxic treatments are a necessary to address this complex debilitating disease. Axatilimab is an antibody to colony stimulating factor 1 (CSF-1), a tyrosine kinase receptor. CSF1R signaling dependent macrophages and monocytes are key mediators of inflammation and fibrosis in chronic GVHD, and thus, this therapy offers a targeted approach. Here we summarize the key clinical studies that have been performed to date of this novel therapy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"409-418"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer. 质子泵抑制剂降低纳武单抗在不可切除的晚期或复发胃癌中的疗效。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-04-14 DOI: 10.1080/1750743X.2025.2491300

Masahito Shibano, Masaya Takahashi, Hitomi Nakatsukasa, Yusuke Ishigami, Takahiro Toyokawa, Koichi Taira, Tomoya Kawaguchi, Yasutaka Nakamura, Hiroyasu Kaneda

{"title":"Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer.","authors":"Masahito Shibano, Masaya Takahashi, Hitomi Nakatsukasa, Yusuke Ishigami, Takahiro Toyokawa, Koichi Taira, Tomoya Kawaguchi, Yasutaka Nakamura, Hiroyasu Kaneda","doi":"10.1080/1750743X.2025.2491300","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2491300","url":null,"abstract":"Background: Proton pump inhibitors (PPI) have been shown to decrease the efficacy of immune checkpoint inhibitors in patients with various cancer types. However, there are few reports on their effect on patients with gastric cancer (GC). Therefore, we investigated the efficacy of nivolumab in patients with GC receiving PPI.Methods: This retrospective study analyzed data of patients who received nivolumab monotherapy for unresectable advanced or recurrent GC at Osaka Metropolitan University Hospital between September 2017 and December 2021. The primary and secondary endpoints were progression-free survival (PFS) and overall survival (OS), respectively. PPI use was defined as within 30 days before and after initiation of nivolumab monotherapy.Results: Seventy-seven eligible patients were included in this analysis. PPIs were used in 33 patients, while 36 patients had a previous gastrectomy. Multivariate analysis revealed that only PPI use was an independent predictor of PFS (hazard ratio [HR] 1.93, 95% confidence interval [CI] 1.03-3.64, p = 0.042). Contrastingly, PPI use was not an independent predictor of OS.Conclusion: PPIs may reduce the efficacy of nivolumab, and their use should be carefully considered in patients receiving nivolumab.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"17 5","pages":"331-338"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model. 在结直肠癌模型中，溶瘤呼肠孤病毒联合PD1-PDL1抑制剂增强CEA免疫治疗的效果。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-05-12 DOI: 10.1080/1750743X.2025.2501926

Atefeh Yari, Seyed Younes Hosseini, Sanaz Asiyabi, Nazila Hajiahmadi, Mohammad Farahmand, Taravat Bamdad

{"title":"Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.","authors":"Atefeh Yari, Seyed Younes Hosseini, Sanaz Asiyabi, Nazila Hajiahmadi, Mohammad Farahmand, Taravat Bamdad","doi":"10.1080/1750743X.2025.2501926","DOIUrl":"10.1080/1750743X.2025.2501926","url":null,"abstract":"Aim: The effectiveness of immunotherapy with tumor associated antigen vaccines can be enhanced by combining oncolytic viruses with immune checkpoint inhibitors. This study evaluates the efficacy of oncolytic reovirus in combination with an adenovector expressing carcinoembryonic antigen (Ad-CEA) and a programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor in a mouse model.Methods: Mice bearing CEA-expressing CT26 tumor cells were immunized with Ad-CEA along with a PD-1/PD-L1 inhibitor. Subsequently, three doses of reovirus were injected into the tumors. Tumor size, histopathological examination, CD8 and FOXP3 expression, the cytotoxicity of spleen T cell lymphocytes, and the secretion of Interferon-γ (IFN-γ) and Tumor necrosis factor- α (TNF-α) were examined.Results: The triple therapy used in this study resulted in the lowest tumor growth and the highest level of cytotoxic immunity. The Foxp3 levels in the tumor microenvironment and TNF-α secretion decreased compared to other control groups. Additionally, this group exhibited the lowest number of mitotic figures and the highest amount of tumor-infiltrating lymphocytes.Conclusion: The combination of tumor vaccines with oncolytic viruses significantly improves treatment efficacy. Furthermore, inhibiting the PD-1/PD-L1 interaction during vaccination and also with virotherapy enhances immunovirotherapy by reducing immunosuppressive effects and stimulating the immune system, leading to improved therapeutic outcomes.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"425-435"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0